Compare Organon & Co. Common Stock (OGN) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs J M Smucker Co — how do they compare? Organon & Co. Common Stock trades at $13.77 (market cap $3.61B), while J M Smucker Co trades at $126.29 (market cap $13.02B). The key difference: J M Smucker Co is far larger — about 3.6× Organon & Co. Common Stock's market cap, and J M Smucker Co pays the higher dividend (3.68%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and J M Smucker Co for 74 Days on average.
| OGN | SJM | |
|---|---|---|
Market Cap | $3.61B | $13.02B |
Volume | 1,808,049 | 1,012,147 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $132.34 |
52-Week Low | $5.70 | $89.53 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $11.03B | $19.87B |
Dividend Yield | 0.58% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SJM trades at $121.33, up 1.09% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows robust analyst support with a $138.46 consensus target, though a high P/E of 56.93 reflects premium valuation. Recent news highlights strong growth in key brands like Uncrustables and raised FY27 EPS guidance to $10.50–$11.00, while cash flow trends improved in 2025.
Outlook is positive with earnings momentum and dividend stability, but risks include volatile profitability, high debt, and competitive pressures. The stock offers growth potential if execution continues, yet investors face margin compression and macroeconomic sensitivity in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
